Related by context. All words. (Click for frequent words.) 82 viii 76 iv 74 ix 72 iii 70 vi 69 xiii 68 xii 68 xvi 67 xviii 67 xxii 66 xvii 66 Immtech clinical trials 66 xv 65 xix 65 ii 65 xxi 61 xiv 61 xi 61 xxvi 59 xxv 58 xxvii 58 xxiv 57 ourability 57 Immtech scientists 56 xxviii 56 xxiii 54 governmental approvals 53 DSL.net s 53 substantial indebtedness 53 risksassociated 53 changesin 53 successfully integrate 53 related thereto 53 collect reinsurance recoverables 53 Pure Biofuels ability 53 regarding Heska 52 otherfactors 52 relatedto 52 contingent guaranties 51 incur unanticipated 51 ability tosuccessfully 51 unanticipated difficulties 51 risks associatedwith 51 general economicconditions 51 lender consents 51 without limitation 51 xxxii 50 requirements xxii 50 withrespect 50 limitedto 50 notlimited 50 theability 50 PharMerica LTC Transaction 50 economicconditions 50 Thalomid R 50 obtaining regulatory approvals 50 unanticipated 49 adversely affect 49 Crisa acquisition 49 successfully commercialize 49 materially adversely affect 49 acquisitions dispositions 49 without limitation Terremark 49 affecting Amarin 49 prepayment speeds loan originations 49 VIOXX Lawsuits 49 causeactual results 49 multiple lease terminations 49 permitting timelines 49 relating 49 Unitholder liability 49 party payors 48 Projects Initiation 48 PGP Acquisition 48 deploy MDCE services 48 HANA MAX 48 [013] 48 inventory obsolescence 48 statementsregarding 48 vii viii 48 § #-#-# b [003] 48 affirmative covenants 48 legal proceedings xxi 48 Heska reliance 48 vii IBC 48 adversely affecting Cubist 48 #.#-# b [001] 48 rapid technological 48 arenot limited 48 including withoutlimitation 47 couldcause 47 incurrence 47 suchforward looking 47 communicate differentiations effectively 47 orotherwise 47 postretirement benefit obligations 47 Mago ® 47 representations warranties covenants 47 expenses associated therewith 47 EMPOWER pivotal trial 47 heading RISK FACTORS 47 materially adversely affected 47 CFR #.#b 47 #.#-# b [002] 47 iii iv 47 currency fluctuations imprecision 47 party VLSI fabrication 47 nonoccurrence 47 aresubject 47 ourproducts 47 refinance indebtedness 47 SANCTURA SANCTURA XR VANTAS 46 PLAVIX R patent 46 FierceGovernmentIT tracks 46 market PolyHeme commercially 46 vii Dynamic 46 otherrisks 46 manufacture PolyHeme 46 gastrointestinal GVHD include 46 theCompany 46 securityholder approvals 46 associatedwith 46 xv licensing 46 fluctuations 46 Shire plc Attention Deficit 46 technological obsolescence 46 Johnell O 46 Sepracor anticipates 46 anduncertainties 46 Bioenvision dependence 46 Risks uncertainties 46 Cerro Negro concession 46 unitholder liability 46 results ofoperations 46 differ materiallyfrom 45 impactof 45 CompanyaEUR TM s 45 consummating acquisitions 45 vi vii 45 ADA CS 45 InnSuites Hotels 45 Item IA 45 associated therewith 45 risksand uncertainties 45 Company noncontributory defined 45 affecting mortality morbidity 45 d Reflects 45 adversely affect Waste Connections 45 risks associated therewith 45 i #.# subds 45 TrueKnowledge Platform TM 45 market fluctuations investee 45 pricing pressures 45 BioSante licensees 45 SeraCare competitors 45 HealthGate ability 45 futureresults 45 risks anduncertainties 45 orother 45 adverse determinations 45 P. #a 45 ultimate recoverability 45 DTR #.#.# b 45 risks associated 45 SUPPRELIN LA DELATESTRYL 45 Black Canyon mica 45 involverisks 45 CORLUX CORT # 45 Consists 45 Colo. Sess 44 MTI MTI Micro 44 i# implanters 44 § #.#-# [007] 44 xvi beer 44 xi unanticipated 44 DIP Loan 44 CAUTION ANY ATTEMPT 44 retrocessional coverage 44 TranSwitch indebtedness 44 SURETY LICENSES c 44 tenant bankruptcies 44 PLIVA acquisition 44 iii Cubist 44 NxStage anticipates 44 j 44 periodic redeterminations 44 PolyHeme successfully 44 Financing Condition 44 work stoppages slowdowns 44 xxxiii 44 couldcause actual results 44 difficulties foreseeing 44 Bioaccelerate compounds under 44 renegotiation nullification 44 work stoppages quarantines 44 dimesylate Attention Deficit 44 collaborations Pharmacopeia 44 distinguishing MDCE products 44 areforward looking 44 delinquencies defaults 44 Nortel strategic alliances 44 SumTotal Systems filings 44 constitutes discloseable transaction 44 c Relates 44 adversely impact 44 regardingthe 44 Lenfest ii 44 non capitalizable 44 SANCTURA SANCTURA XR NEBIDO 44 Cautionary Disclosures 44 c html plugins 44 OSI Pharmaceuticals filings 44 ARLP Partnership 44 Textainer expectation 44 Form #KSB filed 44 Transeastern JV 44 Alnylam dependence 44 differ materially fromthose 44 OraTest R 44 Yima project 44 negatively impact 44 § #-#-# [005] 44 JLG acquisition 44 product introductions 44 xiv unanticipated 44 maydiffer materially 44 bone marrow fibrosis 44 Insolvency Proceedings 43 Somaxon ability 43 Convertible Notes tendered 43 Equinix filings 43 § #.#-# [004] 43 - - [090] 43 thereunder 43 thereof 43 Legal #.# 43 suchstatements 43 USC § #f 43 TP# CETi 1 43 xiv licensing 43 adverse 43 productsand services 43 Idenix anticipates 43 Prelude SkinPrep Systems 43 postretirement benefit plans 43 Auxilium anticipates 43 MOSAID litigation 43 VIOXX Product 43 Ferlay J et al 43 forecasted timelines 43 postretirement benefit 43 Gastroesophageal Reflux 43 EcaFlo TM 43 franchisees licensees 43 Liquor Stores LP 43 render PolyHeme obsolete 43 Iusacell Celular 43 ofsuch 43 persistency mortality 43 uncollectible accounts receivable 43 EHSK 43 indebtedness covenant 43 f h 43 affecting IsoTis 43 Varvarinskoye Project 43 tarmac strandings Hanni 43 SearchHelp communications 43 LPM TM 43 Secure Computing periodic 43 uncertaintiesthat 43 Atheros Quarterly Report 43 novel therapeutic modality 43 affect NYMET Holdings 43 - -Billeaudeau 43 differmaterially 43 Company 43 successfully integrate Legerity 43 transport cystine 43 adversely affect FNB 43 theavailability 43 resulting therefrom 43 successfully commercialize Silenor 43 Excluding acquisitions divestitures 43 Liability Lawsuits 43 HF Lenfest member 43 d Represents 43 #.# subd [003] 43 Manufacturer OEM 43 FGIC insured 43 diminishing quantities 43 Lasertel subsidiary 43 ADSI reliance 43 contingently liable 42 Refinancing Transactions 42 MorAmerica Capital 42 maycause actual results 42 materially impair 42 xxix 42 VYVANSE TM lisdexamfetamine 42 thereby negatively impacting 42 Nortel Networks strategic alliances 42 AngelCiti expectations 42 competitively procured pursuant 42 Candente relies upon 42 AspenTech periodic reports 42 incorporating FalconStor 42 EPIXTAR 'S 42 Shire Attention Deficit 42 VeraTag assays 42 includingstatements regarding 42 itsproducts 42 assorted pigments resins 42 risks unanticipated reclamation 42 marketconditions 42 vii Cubist ability 42 GrowthWorks refers 42 Filtran Microcircuits Inc. 42 Accurel 42 commercialize ZYFLO CR 42 acquisitions divestitures restructurings 42 dispositions joint ventures 42 eTelcharge.com Inc. 42 technological innovations adversely affecting 42 FalconStor OEM 42 Priszm LP 42 regulatory authorizations 42 cadence regulatory approvals 42 looking statements.These 42 involve risks anduncertainties 42 #.#-# Affirmative Action 42 operated bakery cafes 42 ore densities 42 CompAir acquisition 42 economically recoverable coal 42 contingent liabilities 42 USC § #a [002] 42 Carrier Ethernet www.soapstonenetworks.com 42 RPTN common 42 adversely affect Hologic 42 #,# -SPIN BOLDAK Afghanistan 42 molecular immunohematology products 42 anyforward looking 42 Offerors Commercial applies 42 Puricase PEG uricase 42 adversely affect Univest Corporation 42 liabilities slippage 42 intercompany indebtedness 42 Market Disruption 42 toreflect 42 visit http:/www.nationwide.com 42 counterparty creditworthiness 42 g h 42 TRISENOX R 42 andmarket 42 Wikifamilies 42 unfavorable geologic 42 uncertainties 42 early extinguishments 42 Proposed Arrangement 42 EcaFlo R 42 debt extinguishments 42 proprietary Capillary Aerosolization Technology 42 Questcor intellectual property 42 timing rescheduling 42 ceded reinsurance 42 arebased 42 collectibility 42 § #-#-# b [001] 42 SonoPrep device 42 commercialize BiDil 41 payor acceptance 41 - -Commey 41 historicalfacts 41 materially differ 41 thereto 41 LOPROX R 41 SB# Provides 41 BioGold Fuels 41 may diverge numerically 41 incorporate CXA 41 TFC receivables 41 c SIGA 41 Repl. 41 differ materially 41 #,#,# #,#,# -LAS VEGAS MGM Resorts 41 Genitope Corporation filings 41 - Expenses [012] 41 XP# XP# 41 Hyperactivity Disorder ADHD 41 incorporate proprietary Microvolt 41 MGCD# MGCD# [001] 41 dispositions financings 41 cause actualresults 41 Enpath ability 41 PD2i Analyzer ™ 41 Variable annuities involve 41 tomaintain 41 liquidating distributions 41 cause actual resultsto 41 expropriation nationalization 41 affecting BEO Bancorp 41 Rexahn licensees 41 VimpelCom disclaims 41 filingswith 41 subjectto 41 Rexahn actual 41 Absentee bids shall 41 changes Decorize dependence 41 Agreement constitutes discloseable 41 andbusiness 41 n h r 41 #.#-# [020] 41 operated bakery cafe 41 constitute discloseable transaction 41 e# periodic 41 unanticipated geological 41 ENABLE Phase 2 41 adversely affecting 41 RXi Pharmaceutical Corporation 41 RICP 41 capture exosomes 41 EGRIFTA TM 41 expressed orimplied 41 ad valorem taxing 41 andgeneral 41 Bo Scaife TE 41 Second Supplemental Indenture 41 relating thereto 41 mergers consolidations 41 borrower depositor 41 Prochieve R 41 substantiate CytoCore expectations 41 Restated Revolving Credit 41 without limitation EMRISE 41 Partially offset 41 retail industries repositionings 41 subclassified based 41 #.#-# Equal Opportunity 41 -#,# -#,# -#,# -#,# [003] 41 reasonably determinable 41 DCVax R Prostate 41 CAUTIONARY STATEMENT Statements 41 incidental thereto 41 uncertainties materialize Shire plc 41 - - Total [039] 41 withoutlimitation 41 concerning AudioCodes 41 opioid tolerance 41 supplemental indenture containing 41 inherent uncertainty 41 exposes InterMune 41 - - [092] 41 Merger Transactions 41 theforward looking 41 date xvii Conversion 41 awakening feeling unrefreshed 41 x fluctuating beryllium 41 obligations hereunder 41 todiffer materially 41 Omtool periodic reports 41 accounting pronouncements 41 minerals inc 41 uncollectability 41 heading ITEM 1A 41 NJSA #:#-# [004] 41 MIGENIX assumes 41 Kyowa Kirin 41 Company nanocrystalline materials 41 love veronica Mars 41 xviii currency 41 Petrowest 41 i# implanter 41 Proposed Financing 41 SILENOR ™ 41 andoperating 41 Biogold Fuels 41 amino acid cystine accumulates 41 andother 41 Modifiable 41 ti es 41 postretirement benefits 41 Rosetta dependence 41 Verenium dependence 40 - - [108] 40 obsolete inventory 40 - - [085] 40 deCODE filings 40 TRIOLEX HE# APOPTONE HE# 40 offuture 40 Compans 40 ofnew 40 OPAXIO pixantrone 40 Excess Cash Flow 40 b Reflects 40 Xechem Nigeria 40 reflect VIQ Solutions 40 Consists primarily 40 BY AN ENTRANT 40 § #-#.# [003] 40 COPL 40 DJO Merger 40 sublease recoveries 40 Form 8K #K 40 payer reimbursement 40 Cytogen dependence 40 andeconomic 40 CFR #.# [002] 40 - - Nforecaddie 40 - Effect [009] 40 file INDs 40 retain drilling rigs 40 affecting ChinaNet 40 USC § #u 40 VIACOM INC. AND SUBSIDIARIES 40 Factors influencing 40 cause actual 40 #,#,# #,#,# -DH Ellis Burks 40 #.# 5T 40 factors APPY 40 EcaFlo ® equipment 40 Senior Secured Term 40 TriPath Oncology 40 product discontinuances 40 theseforward looking 40 Knoxville MSA 40 Prospectuses contain 40 #,#,# #,#,# -shameful betrayal 40 Terremark filings 40 CFR § #.# [004] 40 distinguishing GigaBeam products 40 Invitel Holdings operates 40 infringed misappropriated invalid 40 Enhance Biotech 40 carryforwards 40 #,#,# Commitments 40 SIFT Rules 40 unconsolidated investments 40 #.# subd [004] 40 Jupiterimages respective 40 Bioenvision compounds under 40 OREO valuation 40 uncertainties materialize Shire 40 eTag assays 40 pharmacotherapeutics 40 #,#,# [023] 40 transactions contemplated 40 Scheduler Plus 40 ii Immtech ability 40 x Immtech 40 INTEGRILIN R eptifibatide Injection 40 molecular immunohematology 40 - Operating [010] 40 UMZ deposit 40 theSecurities 40 DFAR #.#-# 40 cash fl ows 40 newproducts 40 Kanis JA 40 Orosi Mill project 40 NEG Holding 40 looking statements.Such 40 w # yQ 40 Receivable purchasing 40 supplemental indenture effecting 40 SANCTURA R 40 MGCD# MGCD# [002] 40 offerings visit www.balqon.com 40 LAE reserves 40 statements arebased 40 unconsolidated investees 40 React NTI 40 anticipated drydocking 40 b Excludes 40 embolic coiling 40 actualresults 40 DIP Facility 40 manufacture RISPERDAL CONSTA 40 LOUIS Oshiomogho Atogwe 40 h g 40 #,#,#,#,# [010] 40 ecommerce marketplaces 40 reject unexpired 40 - - NetGranara 40 regulatory approvals 40 Sunesis clinical trials 40 competing steel minimills 40 commercialize technological innovations 40 inaccurately estimating 40 MicroTel 40 InfoSearch filings 40 #,#,#,# [015] 40 Senior Secured Debentures 40 #.#-# [005] 40 forwarda ^ looking 40 tosuccessfully 40 -Tommy Salo 40 USC § #c 40 Zi OEM 40 Proposed Transactions 40 Xantic acquisition 40 affecting Pennichuck Corporation 40 forward lookinginformation 40 dispositions 40 Fampridine SR Acorda Therapeutics 40 Achillion anticipates 40 - Operating [020] 40 h r 40 intellectualproperty 40 reinsurance recoverables owed 40 ADVENTRX 40 Earnout 40 BioForce Nanosciences actual 40 transportation storage terminalling 40 novel ZFP TFs 40 Securities andExchange Commission 40 without limitation Newlook 40 reflect Ronn Motor 40 VELCADE therapy 40 raw materials subassemblies 40 customers licensees licensors 40 Osteoporotic fractures 40 Phyto Source LP 40 KRYSTEXXA TM 40 Pervasip actual 40 Chase Kishner 40 NASDAQ Minimum Bid 40 Congoleum undertakes 40 requisite regulatory approvals 40 ePort devices 40 Disruptions uncertainty 40 PAIVIS actual 40 punitive incidental 40 Continuous Disclosure Defaults 40 - - [107] 40 affecting OmniComm 40 RR Donnelley periodic filings 40 #,#,# #,#,# - [007] 40 § #.#-# [006] 40 Income Tax Regs 40 involve risksand uncertainties 40 activate telomerase 40 #,#,# Deferred [001] 40 intellectual property litigations 40 thoseexpressed 40 stockholder approvals 40 interpreting geological 39 primarily attributable 39 Mitsue Pipelines 39 CDFS joint ventures 39 Somatuline R Autogel R 39 i g 39 IEVM 39 Modifiable risk 39 successfully commercialize Iluvien 39 depreciation depletion amortization 39 Franke Mine 39 asset dispositions 39 consents authorizations 39 Syntroleum Process 39 satellite datacasting market 39 Biomerge 39 EVIZON TM squalamine lactate 39 NET INCREASE IN 39 reflecting Maximizer Software 39 FSP #-# 39 CFR § #.# [006] 39 Reorganized Debtors 39 DDJET partnership 39 Diavik Mine 39 reflect GuestLogix 39 - -Abotsi 39 strategic alliances seasonality 39 Exelbine 39 AcryMed Incorporated 39 xxxi 39 NNL failure 39 Subscription Fulfillment Services 39 applicable 39 Inventory write downs 39 dd DISCOUNTS R 39 disable virulence 39 Tecstar Automotive Group 39 Merged Entity 39 OCGA § #-#-#.# 39 PD2i ® algorithm 39 Direct xi Indirect 39 Bond Indenture 39 mortality morbidity 39 t h r 39 Mediaseed R 39 xxxv 39 § #.#-# [002] 39 - - Nesignandsight newsletter 39 GoFish periodic filings 39 prepayment speeds loan 39 personnel xvii inability 39 XL# anticancer compounds 39 Vanda inability 39 AIF identifies 39 CCR5 inhibitors entry 39 maycause 39 Ordinary Unitholders 39 escalation unavailability 39 Acorda Therapeutics intellectual property 39 WDEQ Permit 39 BPE Segment 39 CFR #.# [006] 39 Julius Peppers DE 39 APNB believes 39 CLX Investments 39 Nortel unfunded 39 Acapodene R 39 JUVISTA 39 Oligator R oligonucleotides iv 39 Avivo Corporation 39 Illumigen Biosciences Inc. 39 Indirect Costs 39 See USSG § #A#.# 39 MultiCell bases 39 omecamtiv mecarbil 39 - Operating [009] 39 worsening peripheral neuropathy 39 b 39 Emulex Original Equipment 39 - - Net [034] 39 CHDT SEC Filings 39 Comarco Announces 39 c Reflects 39 Gamecorp 39 - Effect [003] 39 NQCI 39 OTI Annual Report 39 performance compliances certifications 39 - Operating [007] 39 Redishred 39 satisfy indemnification obligations 39 @ y qW 39 reflect Medicago 39 PepsiCo bottling 39 commercialize CorMedix drug 39 bulk amorphous alloys 39 reflect iSIGN Media 39 Fundamental Freedoms ECHR 39 § #a [002] 39 impair Lillian Vernon 39 v Dot VN 39 - - Total [062] 39 consummation 39 #.#-# Evaluation Commercial 39 outstanding indebtedness 39 - Total [007] 39 Entereg TM 39 subparagraph B 39 TranSwitch filings 39 Purchased intangibles 39 Favrille filings 39 y u 39 integrate restructurings consolidations 39 SG &A; 39 enforce MOSAID 39 Theseforward looking 39 technological developments 39 Registrant 39 HB# Provides [001] 39 mergers dispositions 39 uncollectable receivables 39 Creditor Protection Proceedings 39 unforeseen underperformance 39 AvalonBay Communities Announces 39 assumptions underlying 39 CholeraGarde R Peru 39 hpSCs avoid ethical 39 paul dev da 39 CFR § #.# [001] 39 indentures pursuant 39 Lordsburg Mining District 39 Maimon Mine 39 capital expenditures 39 opioid bowel dysfunction 39 asset impairments 39 intercompany arrangements 39 arising 39 § #c 39 EXPENSES Employee Compensation 39 Photowatt France 39 Zemiva TM Trofex TM 39 These statementsare 39 Adjustments Inventory 39 proprietary capillary aerosolization 39 cancellations rescheduling 39 ELESTAT intellectual property 39 Airvana anticipates 39 Reports Inducement Grants 39 PDI periodic filings 39 AirIQ Announces 39 Profile Research AMXL.MX Quote 39 vQsQn 39 DYNACIN R Tablets 39 Assurance Pensions 39 c Excludes 39 bardoxolone 39 Seabulk Challenge 39 Multiemployer Pension Plan 39 OREXIGEN 39 futureperformance 39 - - Income [012] 39 connection therewith 39 CDO financings 39 requisite stockholder 39 § #.# [004] 39 -#,# -#,# [002] 39 BiDil XR drug 39 Partnered Brands segment 39 SmarTire dependence 39 evaluating Questcor 39 successfully commercialize REOLYSIN 39 DARA intellectual property 39 5 lipoxygenase inhibitor 39 necessary regulatory approvals 39 FUTURE INCOME TAXES 39 constituteforward looking 39 Unfavorable 39 - - [074] 39 Rexahn 39 - - Net [051] 39 iv unanticipated 39 Prof. Code § 39 § #-#-# [002] 39 AudioCodes filings 39 Senior Subordinated Noteholders 39 Dimension BST 39 PV module efficiencies 39 § #A.# 39 DELATESTRYL 39 TCA § #-#-# [003] 39 REIT xi 39 andrelated 39 affect Petroflow 39 mandatorily redeemable preferred 39 retroactive restatement 39 especially Copaxone ® 39 Allovectin 7 r 39 PDTI 39 DR #.#.# 39 d SIGA 39 torsemide ER 39 JM Dutton adds 39 PVR lessees 39 table summarizes 39 DeeThree 39 MethyPatch 39 - OperAyscough 39 adversely affect Linktone 39 Defendants misrepresented 39 Zemiva ™ 39 adopting SFAS #R 39 APDN SEC 39 DELETE OR EDIT COMMENTS 39 commercially mineable 39 wv ` 39 BlackPearl Announces 39 Slightly offsetting 39 MFA MBS 39 Remeasurement 39 Discovery Labs 39 - - [016] 39 concerning Wowjoint 39 doubtful accounts receivable 39 y r 39 Diabetic Mellitus 39 intercarrier compensation payments 39 acquisitions divestitures 39 Oxandrin 39 Hedging transactions 39 Ascendiant 39 USED IN FINANCING ACTIVITIES 39 TRISENOX ® 39 KEMET Announces 39 Lease termination 39 applies prospectively 39 See USSG § #B#.# 39 Statement Statements 39 - Total operating 39 Sponsored REITs 39 infringement invalidity 39 negatively affect 39 SIV hinges 39 LandStar Inc. s 39 GEROVA underwrites insurance 39 theimpact 39 - -seemingly unquenchable 39 resultof 39 attaching thereto 39 positive inotropic agents 39 results todiffer materially 39 n h 39 #,# -Marhoefer 39 regarding Anviron 39 Metabasis stockholders 39 #.#-# #.#-# #.#-# #.#-# 38 Detrex stock 38 Indentures governing 38 - - Net [031] 38 prices drydocking 38 tiny pteropod 38 u t 38 Cytokinetics specified 38 Vocus filings 38 Interest Drawdown Date 38 Nortek Holdings 38 postemployment 38 EHT AGN 38 CFR #.# [008] 38 uncertainties materializes FICO 38 Master Commutation Release 38 xi Immtech ability 38 b Represents 38 - Adjusted [017] 38 CFR § #.# [002] 38 Hycroft Mine 38 str = i 38 Operations contained therein 38 acquisitions divestitures joint ventures 38 -Amos Harel Haaretz Correspondent 38 DIP Financing Facility 38 readily determinable 38 subsidiaries Kindred Brookdale 38 While Ambrilia anticipates 38 - Effect [007] 38 customary representations warranties 38 breast tenderness bloating 38 unsecured indebtedness 38 Blue7 38 e mail lifestyle@readingeagle.com 38 Colihues tailings impoundment 38 NOL utilization 38 Bioenvision filings 38 referenced herein 38 vi renegotiation nullification 38 - -Victor Ezeji 38 r l 38 - Effect [014] 38 AcryMed technologies 38 MSCRAMM 38 website www.gladiatorstocks.com 38 sirtuin modulators 38 ecotoxicity 38 - -TEST 38 services visit www.networkengines.com 38 thereby adversely affecting 38 update anyforward looking 38 ZYPS indentures including 38 proba 38 caption Management Discussion 38 Futureway Communications Inc. 38 Hardwoods LP 38 - Total [037] 38 DIFICID ™ 38 MHG Annual Report 38 Subordinate MBS 38 credit carryforwards 38 Erythropoietic therapies may 38 excludes depreciation amortization 38 Sepracor patents 38 Reported Unaudited Condensed 38 FOX MTX 38 NASD Marketplace Rule 38 Kronos TiO2 38 technology crystalline ingot 38 mortality persistency 38 - Operating [019] 38 Applehead I. 38 cyclical downturns affecting 38 OTHER INCOME EXPENSES 38 render Cree 38 resins polymers 38 Override Agreement 38 please visit www.monsanto.com 38 Hyperparathyroidism 38 visit www.bioject.com 38 Warfarin Sodium 38 cargo liftings 38 consolidations restructurings bankruptcies 38 SemCanada 38 LocatePLUS Statements 38 y h 38 See USSG § #D#.# 38 Cellceutix actual 38 current physiologic opioid 38 adverse publicity 38 Regulation XXX 38 TeamStaff filings 38 cyclicality fluctuations 38 Acquired Intangible Assets 38 joint ventures strategic alliances 38 VitroTech 38 Adverse 38 Noncash investing 38 net# [002]